Opioids and cancer prognosis: A summary of the clinical evidence
- PMID: 33482308
- DOI: 10.1016/j.neulet.2021.135661
Opioids and cancer prognosis: A summary of the clinical evidence
Abstract
Pain is a common and devastating symptom among cancer patients. It can be caused by the cancer itself or by certain therapies like surgery, radiation or chemotherapy. Opioids are the first line of treatment for moderate to severe cancer-related pain. Opioids alone or in combination with non-opioid analgesics and adjuvant medications are important components for pain management during the perioperative period for cancer patients. Opioids act on the μ-opioid receptor (MOR), which is expressed in cancer cells and non-malignant cells of the tumor microenvironment. Retrospective studies suggest an association between the expression of MOR in cancers and shorter survival. In addition, recent evidence suggests that opium use and prescription opioids can influence clinical oncological outcomes. In this review, we will summarize the clinical evidence regarding the effect of opioid administration and survival in patients with cancer as well as the current evidence involving MOR expression and cancer progression.
Keywords: Cancer; Mu-opioid receptors; Opioids; Survival.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
-
Effect of Perioperative Opioids on Cancer-Relevant Circulating Parameters: Mu Opioid Receptor and Toll-Like Receptor 4 Activation Potential, and Proteolytic Profile.Clin Cancer Res. 2018 May 15;24(10):2319-2327. doi: 10.1158/1078-0432.CCR-18-0172. Epub 2018 Mar 6. Clin Cancer Res. 2018. PMID: 29511031
-
The Role of Opioids and Their Receptors in Urological Malignancy: A Review.J Urol. 2020 Dec;204(6):1150-1159. doi: 10.1097/JU.0000000000001156. Epub 2020 Jun 9. J Urol. 2020. PMID: 32516030 Review.
-
OPRM1 Methylation Contributes to Opioid Tolerance in Cancer Patients.J Pain. 2017 Sep;18(9):1046-1059. doi: 10.1016/j.jpain.2017.04.001. Epub 2017 Apr 27. J Pain. 2017. PMID: 28456745 Free PMC article. Clinical Trial.
-
Targeting the mu-Opioid Receptor for Cancer Treatment.Curr Oncol Rep. 2021 Aug 3;23(10):111. doi: 10.1007/s11912-021-01107-w. Curr Oncol Rep. 2021. PMID: 34342720 Review.
-
Opioids and Cancer: Current Understanding and Clinical Considerations.Curr Oncol. 2024 May 30;31(6):3086-3098. doi: 10.3390/curroncol31060235. Curr Oncol. 2024. PMID: 38920719 Free PMC article. Review.
Cited by
-
Tumor Necrosis Factor Alpha: Implications of Anesthesia on Cancers.Cancers (Basel). 2023 Jan 25;15(3):739. doi: 10.3390/cancers15030739. Cancers (Basel). 2023. PMID: 36765695 Free PMC article. Review.
-
Mu opioid receptor mRNA overexpression predicts poor prognosis among 18 common solid cancers: A pan-cancer analysis.Front Oncol. 2023 Mar 30;13:1134744. doi: 10.3389/fonc.2023.1134744. eCollection 2023. Front Oncol. 2023. PMID: 37064155 Free PMC article.
-
Kappa opioid receptor internalisation-induced p38 nuclear translocation suppresses glioma progression.Br J Anaesth. 2025 Mar;134(3):759-771. doi: 10.1016/j.bja.2024.09.031. Epub 2024 Dec 30. Br J Anaesth. 2025. PMID: 39741108 Free PMC article.
-
Characteristics of Patients Hospitalized to Community Hospitals With Malignant Brain Tumors and Factors Associated With Discharge Destination.HCA Healthc J Med. 2024 Aug 1;5(4):435-443. doi: 10.36518/2689-0216.1698. eCollection 2024. HCA Healthc J Med. 2024. PMID: 39290478 Free PMC article.
-
Impact of anesthetic factors on prognosis of patients with non-small cell lung cancer after surgery.J Thorac Dis. 2023 Sep 28;15(9):4869-4884. doi: 10.21037/jtd-22-1812. Epub 2023 Jun 21. J Thorac Dis. 2023. PMID: 37868870 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials